| Airdoc 鹰瞳科技 | China | Diagnostics | Retinal image analysis for chronic-disease and cardiovascular risk screening. | Publicly listed, with Class III NMPA device licensing underpinning commercialisation. | 12 |
|---|
| DeepWise 深睿医疗 | China | Medical imaging | Multi-modality diagnostic imaging AI. | Named among the Chinese imaging-AI vendors running large-scale hospital rollouts with real-world validation. | 12 |
|---|
| Helixon | China | Drug discovery | AI protein and antibody design. | Grouped with XtalPi and CSPC among Chinese AI-biotech firms striking large deals with global pharma. | 1 |
|---|
| Infervision 推想医疗 | China | Medical imaging | Imaging AI across chest CT, stroke and oncology workflows. | Among the most established Chinese imaging-AI vendors; partners with domestic hospitals and global pharma for real-world validation. | 12 |
|---|
| Insilico Medicine | China | Drug discovery | Generative AI for target discovery and molecule design, with a robotics lab in Suzhou. | Hong Kong headquartered. IPO on HKEX in December 2025 raising approximately US$293m. | 12 |
|---|
| Shukun Technology 数坤科技 | China | Medical imaging | Cardiovascular, neuro and oncology imaging analysis. | Reached IPO on the back of Class III licensing and hospital rollout. | 12 |
|---|
| Wision AI 希诺医疗 | China | Clinical decision support | Real-time endoscopy AI for polyp and lesion detection. | Listed among China's AI medical-diagnostics companies; procedural AI is a distinct adoption pattern from radiology. | 1 |
|---|
| XtalPi 晶泰科技 | China | Drug discovery | AI plus robotic-laboratory platform for small-molecule discovery and materials science. | HKEX-listed, roughly US$785m raised. Signed a 2025 pipeline collaboration with DoveTree reported at up to US$5.99bn in total potential value.Deal value is potential, milestone-contingent consideration — not revenue. | 12 |
|---|
| Coreline Soft | South Korea | Medical imaging | Lung, cardiac and chest CT quantification, with a screening-programme focus. | Nine radiology FDA clearances, placing it in the FDA AI top 20. Acquired VUNO's LungCT line in early 2026. | 123 |
|---|
| JLK | South Korea | Medical imaging | Stroke and brain-imaging AI. | Secured four US FDA clearances within a single year. Also selected in the August 2026 MOHW consortium programme. | 12 |
|---|
| Lunit | South Korea | Medical imaging | Oncology imaging AI for mammography and chest radiography, plus tissue biomarker analysis. | Reported reaching roughly US$60m revenue. Selected in the August 2026 Ministry of Health and Welfare consortium programme. | 123 |
|---|
| VUNO | South Korea | Clinical decision support | DeepCARS deterioration prediction and cardiac monitoring. | In early 2026 transferred its VUNO Med-LungCT line to Coreline Soft for ₩3.4bn to concentrate on DeepCARS and cardiac monitoring.A rare public example of APAC medical-AI portfolio consolidation rather than growth-at-all-costs. | 12 |
|---|
| EcoNaviSta | Japan | Clinical decision support | Sleep and vital-sign monitoring for care settings. | Acquired in 2025 in a deal reported at US$113.7m — one of the region's largest digital-health exits that year. | 1 |
|---|
| Ubie | Japan | Patient navigation | Physician-supervised symptom assessment guiding patients to conditions and nearby care. | Over US$125m raised. Backers include Google, Japan Post Capital, NTT DOCOMO and Seven-Eleven Japan. Partnership with Mayo Clinic; expanding into the US.The corporate-strategic investor base is characteristic of Japan and shapes distribution more than the capital does. | 123 |
|---|
| Holmusk | Singapore | Real-world evidence | Real-world evidence platform for behavioural health and chronic disease. | US$21.5m Series A led by Optum Ventures and Health Catalyst Capital, with Heritas Capital participating; expanding US operations.Evidence infrastructure rather than a clinical device — a different and often overlooked adoption path. | 1 |
|---|
| MiRXES | Singapore | Diagnostics | RNA-based early cancer detection, notably gastric cancer screening. | IPO in 2025 raising approximately US$139m — the largest APAC digital-health exit of that year. | 1 |
|---|
| Qure.ai | India | Medical imaging | X-ray, CT and ultrasound interpretation, with strong deployment in TB and lung screening. | Founded 2016 in Mumbai; roughly US$125m raised including a US$65m Series D. Named in TIME's Most Influential Companies 2025.Describes itself as the world's most deployed healthcare AI. Deployment breadth here is genuinely public-health scale, not pilot scale. | 12 |
|---|
| Annalise.ai | Australia | Medical imaging | Comprehensive chest X-ray and CT brain triage covering a wide finding set. | Cleared in over 40 countries and used in more than 1,000 healthcare facilities including the NHS, supporting care for over 6 million patients annually. US Medicare approved roughly US$240 per scan.The single clearest APAC example of the full chain completing: clearance, then reimbursement, then volume. | 12 |
|---|
| Harrison.ai | Australia | Medical imaging | Parent company of Annalise.ai (radiology) and Franklin.ai (pathology). | Roughly US$252.6m raised in total including a US$112m Series C. Australia's National Reconstruction Fund took a A$32m stake. | 123 |
|---|
